Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Evaluation Of Biomarkers For Cardiotoxicity Of Anthracyclin-based Chemotherapy

F. J. F. Broeyer, S. Osanto, H. J. Ritsema van Eck, A. Q. M. J. van Steijn, B. Ballieux, R. Schoemaker, A. Cohen, J. Burggraaf
Published 2008 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
IntroductionThe clinical assessment of the myocardial damage caused by anthracyclin (ANT)-therapy is difficult. Therefore a study was performed to evaluate non-invasive markers of anthracyclin-induced cardiac effects, with emphasis on course-to-course variation.MethodsEligible for study participation were patients, without known cardiologic abnormalities who did not use cardiotoxic medication (except for ANT-therapy), who had previously completed at least three cycles of anthracyclin-containing chemotherapy (n = 14) and patients who were ANT-naïve and who were scheduled to receive doxorubicin-containing chemotherapy (n = 12). Seven patients in this last group also completed at least three cycles and were available for follow-up assessments; thus a total population of 21 patients (12F/9M) completed at least three courses ANT-chemotherapy. In these patients blood samples and ECG-recordings were taken within 6 months after completion of ANT-therapy. In 12 patients (10F/2M) assessments were also done before, immediately afterwards and at 24 h after each course of ANT.Results and ConclusionsIn the patients who completed chemotherapy, NT-proBNP was 277% (n = 21; 95% CI: 86–661%, P < 0.001) higher compared to healthy volunteers. During the first course NT-proBNP rose 269% (n = 12; 167–409%, P < 0.0001) at 24 h post-administration. The linear corrected QT (QTcL) directly after the first administration of ANT increased by 9.56 ms (n = 12; 3.85–15.27, P < 0.001) and this prolongation was still present at 24 h, 11.48 ms (n = 12; 5.61–17.34, P < 0.0001). Both NT-proBNP and QTcL returned to baseline before the start of the next course and a similar pattern was observed during each course. NT-proBNP and QTcL may be useful markers for course-to-course evaluation of anthracyclin-induced cardiotoxicity.
This paper references
Elevated B-type natriuretic peptide levels after anthracycline administration.
T. Suzuki (1998)
BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases.
M. Silver (2004)
Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury.
S. Lipshultz (1997)
Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction
G. Daugaard (2005)
Cardiac troponin I in patients with hematologic malignancies
E. Missov (1997)
The relationship between QT intervals and mortality in ambulant patients with chronic heart failure. The united kingdom heart failure evaluation and assessment of risk trial (UK-HEART)
P. Brooksby (1999)
Annexin V imaging of acute doxorubicin cardiotoxicity (apoptosis) in rats.
R. Bennink (2004)
Serum troponin T levels and echocardiographic evaluation in children treated with doxorubicin
E. Kısmet (2004)
Apoptosis and anthracycline cardiotoxicity
A. Thorburn (2006)
NT-ProBNP: the mechanism behind the marker.
C. Hall (2005)
Fiducial segment averaging to improve cardiac time interval estimates.
H. J. Ritsema van Eck (2002)
A more accurate method to estimate glomerular Wltration rate from serum creatinine: a new prediction equation. ModiWcation of diet in renal disease study group
AS Levey (1999)
Prolongation of QTc Interval after Postoperative Nausea and Vomiting Treatment by Droperidol or Ondansetron
B. Charbit (2005)
Anthracycline-induced cardiotoxicity.
R. Hrdina (2000)
Circulating atrial natriuretic peptide plasma levels as a marker for cardiac damage after radiotherapy.
J. Wondergem (2001)
Congestive heart failure in patients treated with doxorubicin
S. Swain (2003)
The cardiotoxicity of chemotherapeutic drugs.
A. Allen (1992)
Risk factors for doxorubicin-induced congestive heart failure.
D. V. Von Hoff (1979)
Adriamycin cardiomyopathy: pathophysiology and prevention
P. Singal (1997)
Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity.
A. P. Launchbury (1993)
Apoptosis in adriamycin cardiomyopathy and its modulation by probucol.
D. Kumar (2001)
Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine
M. Weber (2006)
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
G. Minotti (2004)
Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis.
O. Arola (2000)
Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data.
S. Masson (2006)
Diagnosis of Myocardial Injury by Biochemical Markers: Problems and Promises
B. R. Malasky (2002)
cTnT can be a useful marker for early detection of anthracycline cardiotoxicity.
S. Kilickap (2005)
Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy
D. Cardinale (2004)
Effect of Compensated Renal Dysfunction on Approved Heart Failure Markers: Direct Comparison of Brain Natriuretic Peptide (BNP) and N-Terminal Pro-BNP
A. Luchner (2005)
Cardiac troponin T and creatine kinase MB mass concentrations in children receiving anthracycline chemotherapy.
F. Fink (1995)
Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients.
M. T. Meinardi (2001)
A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation
A. Levey (1999)

This paper is referenced by
Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1.
Hui-Ming Chang (2017)
The Role of Notch in the Cardiovascular System: Potential Adverse Effects of Investigational Notch Inhibitors
P. Rizzo (2015)
Co-delivery of IL17RB siRNA and doxorubicin by chitosan-based nanoparticles for enhanced anticancer efficacy in breast cancer cells.
V. Alinejad (2016)
Review Article Cardiomyopathy Associated With Cancer Therapy
Anthony F. Yu (2014)
Biomarkers in cancer therapy related cardiac dysfunction (CTRCD)
R. Moudgil (2018)
Adjuvant Systemic Therapy of Breast Cancer
F. Schuetz (2011)
Effect of anthracyclines and isoflurane on QTc interval
Archana Venugopal (2014)
Prevention is Better than Cure - Preventing Chemotherapy Induced Cardiomyopathy
W. Qureshi (2013)
Drug-induced QT interval prolongation in cancer patients
T. Becker (2010)
Hormone therapy with tamoxifen reduces plasma levels of NT-B-type natriuretic peptide but does not change ventricular ejection fraction after chemotherapy in women with breast cancer
F. Silva (2015)
Molecular basis of cancer-therapy-induced cardiotoxicity: introducing microRNA biomarkers for early assessment of subclinical myocardial injury.
Hardip Sandhu (2014)
Exercise Prevention of Cardiovascular Disease in Breast Cancer Survivors
A. Kirkham (2015)
Using biomarkers and early prophylactic treatment to prevent cardiotoxicity in cancer patients on chemotherapy : biomarkers : detection and treatment of cardiotoxicity
G. Bacchiani (2012)
Prevención de la cardiotoxicidad en pacientes que reciben quimioterapia
Florenzano Urzua Fernando (2012)
Powikłania kardiologiczne po chemioterapii - patomechanizm, diagnostyka, leczenie i zapobieganie
J. Dudziak (2009)
Using cardiac biomarkers and treating cardiotoxicity in cancer.
Alessandro Colombo (2013)
Orally administered anti-cancer nanocarriers loaded with therapeutic proteins
Ganesh Mahidhara (2012)
Modern diagnostic methods of anthracycline cardiotoxicity in lymphoma patients
Beata Kumiega (2012)
Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial
M. Fiegl (2011)
Role of biomarkers in chemotherapy-induced cardiotoxicity.
D. Cardinale (2010)
Evaluation of lecithinized human recombinant super oxide dismutase as cardioprotectant in anthracycline-treated breast cancer patients.
F. J. F. Broeyer (2014)
Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.
E. Christenson (2015)
Are Biomarkers Predictive of Anthracycline-Induced Cardiac Dysfunction?
A. Malik (2016)
Alternative Biomarkers for Combined Biology.
Y. Kim (2017)
Cardiomyopathy associated with cancer therapy.
A. Yu (2014)
Approccio cardiologico al paziente sottoposto a trattamento antitumorale. Documento primo
L. Boccardi (2011)
Biomarkers for monitoring chemotherapy-induced cardiotoxicity
Liyun Cao (2017)
patients & modify CV risk factors Strategies for reducing cardiotoxicity : Anthracycline : Dose reduction , continuous infusion , liposomal doxorubicin , dexrazoxane Trastuzumab : Avoid concomitant anthracycline VSP inhibitors : Treat hypertension
Hui-Ming Chang ()
Short-term QT variability: A marker for reduced repolarization reserve in anthracyclin therapy
HJ Ritsema van Eck (2009)
Model-Based Evaluation and Optimization of Cardiac Monitoring Protocols for Adjuvant Treatment of Breast Cancer with Trastuzumab
J. G. C. Hasselt (2012)
Anthracycline or trastuzumab-related cardiotoxicity: do we have a predictive biomarker?
M. Chaudry (2016)
Oral administration of iron-saturated bovine lactoferrin–loaded ceramic nanocapsules for breast cancer therapy and influence on iron and calcium metabolism
Ganesh Mahidhara (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar